Genprex

News

In pharma, cancer is king

Inside the industry’s quest for its next crowning achievement in oncology.

Read More

Highlighting Genprex’s Medical Advisors on National Doctors’ Day

March 30 marks National Doctors’ Day, an annual holiday when we can all acknowledge and show appreciation for our physicians who help save lives everywhere.

Read More

Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders

These board additions will enhance the Company’s ability to execute on key corporate initiatives.

Read More

Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives

These seasoned industry professionals combined with the company’s newly strengthened balance sheet will drive key clinical programs.

Read More

Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview

Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.

Read More

Texas company licenses University of Pittsburgh gene therapy that could cure diabetes

A UPMC Children’s Hospital of Pittsburgh researcher is crediting a new, supportive environment for entrepreneurs at the University of Pittsburgh for making it possible to license a technology that may one day cure diabetes.

Read More

Genprex to Present at the 2020 LD Micro Virtual Conference

Genprex will present at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.

Read More

The Power Behind Gene Therapy Drug Combinations

Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.

Read More

Austin’s Genprex raises $25.5M with 2 stock offerings

Austin-based biotech firm Genprex is looking for more growth after raising about $25.5 million through two recent stock offerings.

Read More

Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.

Read More